[Capecitabine Combined with Cisplatin As First-Line Therapy in Chinese Patients with Advanced Gastric Carcinoma-a Phase II Clinical Study].
Bing Hu,Ji-Ren Yu,Zhao-Zhang Wen,Yong-Qian Shu,Bao-Cheng Wang,Hao-Ran Yin,Li Chen,Yu-Xian Bai,Jun Liang,Ying Cheng,Lin Shen,Yun Zhou,Hong-Gang Zhang,Jie Li,De-Sen Wan,Shuang Chen,Ting-Zhen Jia,Mao-Lin Jin
DOI: https://doi.org/10.3321/j.issn:0253-3766.2008.12.015
2008-01-01
Abstract:OBJECTIVE:To evaluate the effectiveness and safety of the combination chemotherapy of capecitabine (X) with fractionated administration of cisplatin (C) in Chinese patients with advanced gastric cancer (AGC).METHODS:141 patients with AGC were enrolled between July 2002 and August 2004. All patients had measurable tumor according to the criteria of RECIST, Karnofsky performance status > or = 60, adequate bone marrow, renal and hepatic functions. Prior radiotherapy or adjuvant chemotherapy was not permitted. Patients received oral administration of capecitabine at a dose of 1000 mg/m(2) twice a day on D1-D14, and intravenous infusion of fractionated cisplatin at a dose of 20 mg/m(2)/day on D1-D5. The regimen was repeated every 3 weeks, totally for 6 cycles.RESULTS:Of the 141 evaluable patients, there were 104 men and 37 women, with a median age of 54 years (range, 23 - 80 years). Metastases before chemotherapy were detected in lymph nodes (46.8%), liver (40.4%), lung (5.7%) and other area (10.6%). The median treatment duration was 6 cycles (range, 3 - 6 cycles). The objective response rate (RR) was 36.2% (51/141). The median follow-up period was 17.5 months. The median time to progress (TTP) was 9.0 months, and the median overall survival (OS) was 12.0 months. The most common treatment-related adverse events (grade 3/4) were: hand-foot syndrome (HFS) (2.1%), leucopenia (0.7%), abnormal alanine transaminase elevation (2.8%). There was no treatment-related death.CONCLUSION:Capecitabine combined with fractionated cisplatin is highly effective and well tolerated as a first-line treatment for advanced gastric cancer, with comparable results to 5-Fu plus cisplatin combination therapy.